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Abstract 
Ensuring the objectivity of systematic reviews and meta-analyses (SRMA) begins with 
comprehensive searches into diverse resources mining primary studies. Guidelines for 
systematic reviews recommend authors to routinely search of trial registries to identify 
unpublished studies. In this dissertation, I investigated the utilization of 
ClinicalTrials.gov (CTG), the world’s largest clinical trial registry that contains data from 
clinical trials of products that are subject to United States Food and Drug Administration 
(FDA) regulation, as an information resource in SRMAs. First, I examined the use of 
various information resources including CTG in SRMAs published from 2005-2016, and 
identified the factors associated with their use. Thereafter, to determine the accuracy of 
trial safety data reported at CTG, I compared the data at CTG with that in corresponding 
journal articles and FDA drug reviews. I found that trial safety data at both CTG and 
articles differed frequently from FDA drug reviews, but the differences were modest in 
magnitude. Finally, I repeated published meta-analysis (conducted using data from 
primary study articles) with data at CTG to find that most meta-analysis results were 
reproduced using CTG data. Taken together, this work suggests that CTG should not only 
be searched more often to find primary research for systematic reviews, but that data at 
CTG can also be used to conduct quantitative data synthesis.   
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CHAPTER 1 
Introduction 
Publications of systematic reviews and meta-analyses (SRMAs) have tripled over the last 
decade, without comparable improvement in methodological rigor or reporting 
standards.[1] Meanwhile, studies linking favorable meta-analysis outcomes with financial 
conflicts of interest of authors have highlighted the susceptibility of SRMAs to 
manipulation.[2–4] Amidst these findings, while some have questioned the position of 
SRMAs as the highest level of evidence, [5]others have called for ensuring greater 
objectivity and reproducibility in producing them.[6] A way to ensure the objectivity of 
SRMA results is to perform comprehensive searches into resources mining primary 
literature.[7] However, what constitutes a comprehensive search remains open to 
interpretation,[8] and potential manipulation. 
The purpose of a SRMA is to summarize all scientifically generated evidence on a topic 
of interest. A systematic search for data from a diverse body of evidence is fundamental 
to serve that purpose. In addition to extracting data from published studies, it is important 
to search unpublished studies (also known as grey literature) as research shows that the 
latter have smaller treatment effects than published studies,[9,10] and that inclusion of 
unpublished results can change conclusions of meta-analyses.[11,12] Conversely, failure 
to include unpublished data biases the results towards a positive treatment effect (also 
known as publication bias).[13,14] Research into the evolving use and relative 
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importance of information resources mining published and unpublished research can 
improve the scientific rigor of evidence synthesis. 
Although including both published and unpublished data is important for validity, in 
practice, neither is searching for the unpublished data easy,[15–17] nor are guidelines 
suggesting resources to be searched for unpublished data consistent among each 
other.[18] Most popular biomedical search engines mine only published studies, and little 
consensus exists regarding which resources to look into for unpublished data.[8,19] 
Among the sources of unpublished studies, trial registries established to mine data from 
clinical studies have emerged as a rich source of information over the last decade. 
Registries store information from studies regardless of the success of their outcomes, 
making them an important source for unpublished research.[7] Clinical trials of drugs, 
biologics, and devices must be registered in study registries including ClinicalTrial.gov 
(CTG).[20] CTG, launched in 2000, is currently the world’s largest clinical study registry 
and contains information from clinical trials of products that are subject to Food and 
Drug Administration (FDA) regulation.[21] While studies have documented the underuse 
of registries,[1,22–25] factors that may lead to more widespread inclusion of such 
resources in search strategies have not been studied.  
Querying the registry is important for meta-analysis research as almost half of large trials 
reported in CTG remain unpublished in journals.[26] However, since trialists are also 
required to report data on trial results in CTG, apart from being just a source of 
information on unpublished trials, CTG also acts as a publicly available source of trial 
data. CTG is particularly important in safety data, as recent research has shown that CTG 
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covers a greater number of and a wider range of adverse events (AEs) than published 
articles on primary studies, the traditionally used source of data for quantitative data 
synthesis in secondary research.[27]  
On the other hand, works showing inconsistencies in efficacy[28] and safety[29] results 
published in articles and those reported in registries have questioned the quality of the 
data in registries. Since peer reviewers reviewing articles typically do not have access to 
patient-level data, the reviewers are unable to assess the provenance of the study results. 
Raw data from trials submitted for drug licensing, however, are routinely reviewed by the 
US-FDA, and these medical reviews are made public at Drugs@FDA.com.[29,30] Since 
trialists are legally mandated to submit accurate data to the FDA,[31,32] the FDA 
medical reviews can serve as reference standards to validate the data at CTG and articles. 
A recent study focusing on primary outcome comparison between the medical reviews 
conducted by the FDA, [30] and CTG results found that most primary efficacy reports are 
concordant between the two sources.[33] However, they did not compare the FDA 
reviews and CTG reports with the corresponding published articles. Thus, the need to 
evaluate the concordance between FDA review (the gold standard) and the two test 
resources (CTG and articles) on adverse events remains unaddressed. This is an 
important lacuna, preventing the use of CTG data in meta-analysis research. 
A final question that needs answering before data at CTG can be used to perform 
secondary analysis instead is whether differences in data between two sources cause 
meta-analyses of data at CTG to differ qualitatively from meta-analyses using original-
article data. No consensus exists on the use of the trial data reported at CTG for 
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quantitative data synthesis in meta-analyses.[34] Use of data at CTG, however, might 
provide certain logistic benefits over use of data from published articles. For example, a 
SRMA is a labor-intensive and time-consuming endeavor; one of its most protracted and 
error-prone steps involves extraction of data from reports on primary trials.[35–37] Given 
that the median time between publication of protocols of Cochrane SRs and their final 
publication is 2.4 years,[38,39] and that errors in extracting numerical data pose are 
common,[40] an automated methods of data extraction for meta-analysis research can be 
of benefit. Although recent attempts have automated extraction of qualitative and design-
related variables from published articles,[41] few have automated extraction of numerical 
results, possibly because of heterogeneous publishing formats and reporting standards. 
CTG forms an alternative source that is more amenable to automatic extraction because 
of its uniform reporting format. However, if data at CTG, given its differences from 
article data, qualitatively alters meta-analysis conclusions, its utility in meta-analysis 
research will be limited. Thus, the validation of use of CTG data in meta-analysis 
research is necessary before tools to automatically extract data from CTG can be 
routinely used. 
In chapter 1 of this dissertation, I conduct a situational analysis into the use of CTG and 
other information resources searched to find primary studies for evidence synthesis in 
SRMAs. For this, I track the self-reported use of various information resources in 
SRMAs published between 2005-2016, and identify the resources that are associated with 
low publication bias. 
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In chapter 2, using FDA drug reviews, I examine the discrepancies between published 
article and CTG data, specifically in context of safety endpoints. I examine the frequency 
and magnitude of differences in safety data from clinical trials reported across three 
sources: CTG and journal published articles as index sources and corresponding FDA 
medical reviews as the reference. 
In chapter 3, I repeat meta-analyses from published SRMAs using CTG data instead of 
data from primary articles to investigate whether the use of CTG data materially alters 
conclusions of the SRMAs.  
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CHAPTER 2 
Patterns in use of information resources for evidence synthesis in systematic reviews 
and meta-analyses: 2005-2016 
Introduction 
Commercial publishers are likely to be interested in publishing studies that have positive 
results in alignment with the hypothesis, and thus are “news worthy”. Similarly, industry-
based or academic researchers are likely to be interested in publishing positive results to 
more efficiently use their time in talking about successful products or research, 
respectively. In fact, not only are negative studies published on an average two years later 
than their positive counterparts, they are also are less likely to be published at all.[42] 
Although ignored during publication, however, negative studies assume just as much 
importance as published ones when the aim is to summarize evidence on a topic of 
interest. Importantly, inclusion of results from unpublished studies has been shown to 
alter the results of meta-analysis.[11,12] Thus, searching unpublished studies is important 
for valid meta-analyses. Study registries like ClinicalTrials.gov (CTG) store data from 
both published and unpublished research. For example, Riveros et al. 2013 found that up 
to 50% of trials posted in CTG remained unpublished in peer reviewed journals.[26] 
Registries should thus constitute an important resource for unpublished literature. 
Accordingly, 2012 Cochrane guidelines mandate inclusion of study registries and grey 
sources in SRMA search strategies. CTG contains information from clinical trials of 
products that are subject to Food and Drug Administration (FDA) regulation.[21] Other 
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trial registries can be accessed through the World Health Organization (WHO) 
International Clinical Trials Registry Platform (ICTRP), a portal to 16 trial registries 
managed by various national regulatory bodies.[43] Additional repositories of trial 
reports can include regulatory body reports (FDA databases), grant databases, and 
manufacturer websites.[7] Sources of grey literature that are not clinical trials include 
conference abstracts, dissertations, book chapters, policy documents, and specialized grey 
literature databases, among others.[17] In order to avoid skewing meta-analysis results 
towards positive outcomes, a systematic search for both published and unpublished 
studies are necessary. However, systematic evidence on the resources searched, and what 
constitutes a comprehensive search, is lacking. 
In this chapter, I examined the use of various information resources by randomly 
sampling SRMAs published in each year from 2005-2016, and identified the factors 
associated with their use. Using network analysis, I explored which resources were 
simultaneously searched in each year. I used interrupted time series to look for changes in 
the use of various information resources following the promulgation of a guideline (in 
late 2012) urging the use of diverse resources in SRMAs. Using logistic regression, I 
sought to identify information sources associated with a reduced likelihood of publication 
bias.  
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Methods 
Searching and eligibility 
I searched PubMed for SRMAs published from 2005 through 2016. I chose the year 2005 
to start search in order to specifically evaluate CTG usage in SRMAs after International 
Committee of Medical Journal Editors (ICMJE) publication rules (2005) which caused 
substantial increase in the trial registration in CTG, an converted CTG into a repository 
of clinical trials with worth looking into before evidence synthesis.  Using search terms 
aimed at finding systematic reviews with quantitative meta-analyses I extracted all 
articles indexed in each calendar year. To focus on articles likely to search CTG for 
unpublished studies, I restricted the search to include articles with human subjects and 
those authored by US-based investigators. The complete search term was: 
“systematic[sb] AND USA[ad] AND (Meta-Analysis[ptyp] AND ("respective 
year/01/01"[PDAT]: "respective year/12/31"[PDAT]) AND "humans"[MeSH Terms])”. 
From those, I randomly selected 100 articles for each year to review manually. I excluded 
articles if they (1) did not find full-texts, (2) did not have a defined and documented 
search strategy, (3) did not perform quantitative data synthesis and meta-analysis, (4) did 
not involve humans, (5) specifically excluded the USA population, (6) used a single case 
experiment design, or (7) had duplicates in another year. Exclusion criteria 1, 2 and 3 
were deemed necessary to allow for imperfect indexing in PubMed. The study flow 
diagram is represented in Fig 1.    
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Data extraction 
Each eligible SRMA article was manually reviewed to extract the data regarding 
publication characteristics and search resources by one of three investigators (me/Kyle 
/Bikramjit: please see preface). Three investigators independently extracted data from a 
set of 10 SRMAs to help achieve uniform extraction. For all reviewed SRMAs, after one 
investigator extracted the data, a second investigator validated the extraction, and 
disagreements were resolved by mutual discussion. 
I collected the information on all online databases and other information resources 
utilized by authors of each SRMA to search for primary studies, as mentioned in the 
search strategy of the SRMAs. Whether or not SRMA authors searched from the 
information resources was noted as a binary variable. I identified 30 information 
resources and retrospectively classified them into four categories: 1. Study registries 
[CTG, ICTRP, regulatory databases (eg, FDA, EMEA), manufacturer database, grant 
websites for funded studies (eg, NIH, Wellcome trust), others (ISTRN, HTA, HSRProj, 
C2-SPECTR, PROSPERO)];2. Resources mining general published literature without 
special focus [Medline, EMBASE, others (Scielo, JSTOR, etc)]; 3 Resources mining 
specialized published literature [Cochrane library, psycINFO, CINAHL, POPLINE, 
regional/language specific database, review collections (eg, EBMR, ACP journal club), 
SportDiscus, HealthStar, International pharmaceutical abstracts, PILOTS]; 4. Resources 
other than registries that include unpublished literature [Conference proceedings, 
dissertations, Scopus, Web of Science, Search engines (eg, Google Scholar), ProQuest, 
BIOSIS, ERIC, Clinical query applications, designated grey literature databases 
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(OpenGrey, Sigle, NTIS), and others (MedScape, manufacturers package inserts, etc)]. 
Salient features of each information resource are described in Appendix 1. 
Information was also collected on each SRMA regarding the nature of primary studies 
(interventional or observational), whether the study involved a pharmacological 
treatment, and the outcomes studied (efficacy outcomes, safety outcomes, others). In 
order to determine the nature of the primary studies, the search criteria in each SRMA 
were looked into: when the specific nature of the primary studies searched was not 
mentioned, primary studies directly were directly examined. In cases where the specific 
nature of the primary studies was not mentioned in the search criteria, and yet only one 
type of primary study (say, interventional) was included in the SRMA, the SRMA was 
classifies to have interventional studies only. The logic for this was that the SRMA 
authors would have anticipated the nature of their primary studies, and searched 
resources accordingly. The nature of the journal in which the SRMA was published were 
noted [general med/surgery journals (general medical journals), journals specializing in 
epidemiology/public health/research methods (methods journals), psychiatry and 
psychology journals (psychiatry journals), specialized journals on sub-disciplines within 
medicine/surgery (specialized medical journals)] along with their impact factors each 
year. A separate class for psychiatry journals was formed because of the fairly distinct 
information resources accessed by this medical discipline. A complete list of all journals 
classified into each of the four groups is provided in Appendix 2. Additionally, it was 
noted if publication bias was statistically assessed, and, if assessed, whether the authors 
deemed publication bias to be present or not.  
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Analysis 
I summarized the characteristics of the SRMAs over the years using percentages of total 
for the year for categorical parameters or mean and standard deviations for numerical 
parameters. Differences in parameters between years were examined using chi-square 
statistics for categorical variables and ANOVA for numerical variables. I tracked the use 
of all 30 information resources over 12 years using bar diagrams. To identify the factors 
predicting study registries, and CTG in particular, I used a logistic regression model with 
their characteristics as independent variables. To identify concurrent use of similar types 
of information resources, I constructed the network geometry of articles and the 
information resources in each year. Each information resource formed one node in each 
network, and each node was connected to another by a line if at least one article searched 
both information resources. The thickness of the connecting lines denotes the number of 
articles searching the two resources. Distance between two nodes is given by their 
Euclidian distance, which represents how frequently they are co-searched. To detect the 
presence of homophily (tendency of resources to be associated and, in our scenario, 
searched concomitantly), I used the ANOVA density model.[44] The network densities 
for a year (number of actual ties between nodes/number of all possible ties between all 
nodes with theoretical extremes between zero and one) were calculated. I also used 
interrupted time series analysis to see if there was a change in the use of registries after 
December 2012, when Cochrane guidelines [Methodological Expectations of Cochrane 
Intervention Reviews (MECIR)][34] first mandated using registries as an information 
resource in SRMAs. Assuming a time lag of one year between promulgation of MECIR 
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and publication of SRMAs that might have followed the guideline, I selected 2014 as the 
year from which I could expect the promulgation guideline to show results. Last, I used 
logistic regression adjusted for SRMA characteristics and other resources to identify the 
information resources negatively associated with publication bias. Data were analyzed 
using STATA version 14[45] and UCINET version 6.[46] 
Results 
Characteristics of SRMAs and information sources used 
I retrieved a total of 11,868 PubMed entries using the search terms, and randomly 
selected 100 entries each for each year (1200 entries between 2005-2016). A total of 817 
SRMA articles with an average of 68 SRMAs per year (range: 59-79) were included in 
the final analyses (Fig 1). Table 1 describes the included SRMAs. Of the journals 
publishing the SRMAs, about two-thirds (65.2%) were specialized medical journals, 
while the rest were approximately similar proportions of general medical journals (9.2%), 
psychiatry journals (14.7%), and methods journals (10.9%). The mean impact factor of 
these journals was 4.7 (standard deviation: 4.5). The primary research analyzed by the 
SRMAs included interventional studies in 61.0% cases and observational studies in 
62.9% cases. Almost one third of the SRMAs had a safety parameter as an endpoint 
(32.4%), and one third of the SRMAs examined a pharmacological agent (33.6%). 
Publication bias was statistically assessed in about 45.9% of the SRMAs, of which a third 
(33.1%) found statistical evidence of such bias. Fig 2 represents a comparative picture of 
information resource use in 2005 and 2016. The most common sources used overall were 
	  13	  
Medline/PubMed, EMBASE, and the Cochrane databases in both years. Use of registries 
and Scopus increased substantially from 2005 to 2016. Trends in utilization of registries, 
general and specialized published literature databases, and grey literature sources are 
provided in Appendix 3. 
!!Table!1.!Characteristics!of!systematic!reviews!and!meta8analyses!(SRMA)!included!in!the!study!!
!!Footnote:!None!of!the!variables!were!significantly!different!between!the!years!except!*!frequencies!of!SRMAs!with!an!efficacy!endpoint!(Χ2,!P=0.002)!and!**frequencies!of!SRMAs!where!publication!bias!was!assessed!statistically!(Χ2,!P=0.030).!!!!!
Year% 2005% 2006% 2007% 2008% 2009% 2010% 2011% 2012% 2013% 2014% 2015% 2016%
Number%of%SRMAs%included%
(n)%
66% 59% 65% 74% 71% 69% 65% 64% 62% 68% 75% 79%
General%medical%journals%(%%
of%n)%
15.2% 6.8% 15.4% 10.8% 7.0% 10.1% 12.3% 4.7% 8.1% 5.9% 5.3% 8.9%
Methods%journals%(%%of%n)% 10.6% 10.2% 9.2% 9.5% 12.7% 14.5% 9.2% 6.3% 14.5% 5.9% 17.3% 10.1%
Psychiatry%journals%(%%of%n)% 19.7% 20.3% 18.5% 17.6% 16.9% 13.0% 4.6% 17.2% 16.1% 13.2% 9.3% 11.4%
Specialized%journals%(%%of%n)% 54.6% 62.7% 56.9% 62.2% 63.4% 62.3% 73.9% 71.9% 61.3% 75.0% 68.0% 69.6%
Mean%(SD)%impact%factors%of%
journals%
4.8%
(4.7)%
5.0%
(5.0)%
5.6%%
(7.3)%
5.3%%
(6.0)%
4.6%
(2.9)%
5.1%
(5.6)%
4.8%
(3.9)%
5.2%
(4.0)%
4.8%
(3.5)%
3.3%
(2.0)%
4.7%
(3.9)%
3.9%
(2.9)%
Efficacy%endpoints%%
(%%of%n)*%
42.4% 28.8% 35.4% 37.8% 40.9% 53.6% 53.9% 42.2% 30.7% 48.5% 54.7% 27.9%
Safety%endpoints%
(%%of%n)%
37.9% 30.5% 35.4% 33.8% 38.0% 37.7% 30.8% 26.6% 32.3% 32.4% 32.0% 22.8%
Others%endpoints%%
(%%of%n)%
54.6% 59.3% 55.4% 52.7% 42.3% 47.8% 53.9% 53.1% 67.7% 42.7% 42.7% 51.9%
Pharmacological%agent%
studied%(%%of%n)%
40.9% 27.1% 33.9% 35.1% 42.3% 34.8% 38.5% 15.6% 30.7% 30.9% 37.3% 34.2%
Primary%studies:%
Interventional%(%%of%n)%
65.2% 54.2% 58.5% 60.8% 60.6% 59.4% 56.9% 65.6% 59.7% 63.2% 66.7% 60.8%
Primary%studies:%
Observational%(%%of%n)%
56.1% 61.0% 53.9% 60.8% 67.6% 63.8% 63.1% 68.8% 64.5% 67.7% 60.0% 67.1%
Publication%bias%assessed%(%%
of%n)*%
39.4% 37.3% 30.8% 48.7% 47.9% 40.6% 56.9% 54.7% 45.2% 39.7% 58.7% 48.1%
Publication%bias%identified%%
(%%of%n)%
12.1% 11.8% 6.1% 20.3% 15.5% 17.4% 21.5% 12.5% 11.3% 11.7% 22.6% 20.2%
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Figure 1. Study flow diagram. 
[Footnote 
* 2005 - 2016 n’s: 550, 694, 720, 778, 810, 963, 1107, 1301, 1198, 1071, 1507, 1169 
** 2005 - 2016 n’s: 66, 59, 65, 74, 71, 69, 65, 64, 62, 68, 75, 79] 
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Figure 2. Percentage of SRMAs using each information resource type in the years 2005 and 
2016: Grey bars represent percentage of SRMAs using a resource in 2005 (n=66) and black bars, 
2016 (n=79). Within each class (registries/general literature database/specialized literature 
database/grey literature resource), resources are arranged in decreasing order of usage frequency 
in 2016. Percentages of SRMAs using each information resource are shown in Appendix 3. 
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Predictors of use of different information resources 
I examined factors predictive of searching various types of information resources (Fig 3). 
Appendix 4 describes the factors predictive of searching individual databases. Methods 
journals were strongly associated with the use of registries, grey resources, and 
specialized literature resources. SRMAs used registries more often if a pharmacological 
agent was being studies. There overall use of registries or grey sources did not increase 
over the years. Use of specialized literature databases was more prominent in psychiatry 
journals. Perhaps encouragingly, there was no correlation of journal impact factor and 
greater use. Interestingly, general medical journals showed a correlation with lower use 
of general literature databases. Upon examining the 34 SRMAs that did not use any 
generalized literature database, I found that three were in specialized medical journals, 26 
in psychiatry journals and five in general medical journals. For the five in general 
medical journals, the following resources were used: Cochrane library, Web of Science, 
regulatory and manufacturer websites, sponsoring website, and specialized resources. All 
the five SRMAs were published on or before 2012. 
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Figure 3. Factors associated with use of various information resources: Using a bivariate 
logistic regression model, we derived adjusted odds ratios (boxes) and their 95% confidence 
limits for association of various SRMA characteristics and use of A. registries, B. general 
literature databases, C. specialized literature resources, D. grey literature resources. SRMA 
characteristics are color coded to represent year (dark navy), journal type (blue) with specialized 
medical journals as reference, impact factor (green), primary study type (turquoise), endpoint 
examined in SRMA (grey), and whether pharmacological agents were examined in SRMA 
(purple). Factors associated with each individual data source are shown in Appendix 4. 
* Methods journal always searched general literature databases, causing the odds ratio to be much 
greater than 20, the x-axis scale limit. 
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Networks of information resources 
The motivation behind searching multiple resources for SRMAs is to cast a wider net for 
finding relevant studies. Search strategies are thus most successful when multiple, 
distinctive resources are searched, and searching many resources is not particularly 
helpful unless they have substantial non-overlap. I performed network analysis to 
ascertain the degree of clustering of the different resources searched by the SRMAs over 
the years. Figs 4A and 4B show representative resource networks formed by the SRMAs 
in the years 2005 and 2016, respectively. Each node represents an information resource 
that has been used by an SRMA. A line joins two nodes if any SRMA has used the two 
information resources concurrently, while the thickness of the line denotes the number of 
SRMAs that have searched both resources. The closeness of any two nodes in the 
network depends upon the number of SRMAs that have searched both resources.  
In both networks, the three published literature databases Medline, EMBASE, and 
Cochrane databases form the central resources and are closest to each other, denoting the 
highest degree of co-occurrence in SRMA searches. The network connections increase 
substantially from 2005 through to 2016. However, the presence of published literature 
resources (combining generalized and specialized literature databases, both denoted by 
purple squares) clustered towards the center and registries (denoted by cyan circles) and 
other grey literature resources (denoted by grey triangles) towards the network periphery 
indicates significant amount of co-searching of published literature resources by the same 
SRMAs.  
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ANOVA density models constructed to detect homophily (tendency of resources to be 
associated and, in our scenario, searched concomitantly) confirms that while querying 
multiple databases authors mostly just search analogous resources likely to have high 
degree of overlap. The standardized regression coefficient of co-searching of published 
resources is highest among the possible permutations (0.22, P=0.04). The ranking of 
information resource type co-searches is as follows:1.two published literature databases 
(Coefficient: 0.22, P=0.04); 2. A published literature database and a grey literature 
database (Coefficient: 0.01, P=0.06); 3. A published literature database and a registry 
(Coefficient: - 0.01, P=0.59); 4. Two registries (Coefficient: - 0.007, P=0.43); 5. A grey 
literature database and a registry (Coefficient: - 0.04, P=0.43) (reference combination: 
two grey literature databases).  
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Figure 4. Network of data sources in 2005 and 2016. 
Nodes denoted by cyan circles (     ) for registries, purple squares (   ) for general or 
specialized literature resources, grey triangles (    ) for grey literature resources. Each 
information resource forms one node in each network, and each node was connected to 
another by a line if at least one article searched both information resources. The thickness 
of the connecting lines denotes the number of articles searching the two resources. 
[Nonstandard abbreviations: CTG=ClinicalTrials.gov, other_spec_lit= other specialized 
literature database, other_gen_lit=other general literature database, DesignatedGL= 
designated grey literature database, RegionalDB= regional/language specific database, 
MAcollections= Collections of EBM reviews/ACP journal clubs] 
 
 
 
 
 
2005$ 2016$
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Effect of registry search guidelines on CTG usage in SRMAs 
In 2012, the Cochrane guideline for systematic review and meta-analyses methodology 
first mandated searching from study registries like CTG and ICTRP as well as grey 
resources over and above Cochrane databases. I conducted an interrupted time series 
analysis to see whether or not there was any increase in registry usage after the 
implementation of the guideline (2014-2016) as compared to before its implementation 
(2005-2013). I did not find a significant effect of the guideline on the usage of either use 
of general literature databases, registry, or grey sources (Fig 5A, B, D). The use of 
specialized literature databases (Fig 5C) and the yearly network densities (number of 
actual ties between nodes/number of all possible ties between all nodes with theoretical 
extremes between zero and one) increased from 2014 onwards (Fig 5E). Increasing 
network density denotes an increase in diversity in the usage of information resources in 
SRMAs. Results for individual resources are in Appendix 5. 
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Figure 5. Interrupted time series analysis showing changes in data-resources before and 
after 2014: Analysis for A. registries, B. general literature databases, C. specialized literature 
resources, D. grey literature resources, and E. network densities. For analysis, we used a Praise 
Weinstein autocorrelation model with lag of one year. Black dots represent the actual percentage 
of SRMAs using the resource, while the connecting solid line is the model prediction. P values 
represent the significance of change in resource use after 2014. In each graph the two lines are fit 
to the first 9 data points (black) and again to the last 3 (blue). Results of interrupted time series 
analysis for each individual data source are shown in Appendix 5. 
 
Relative importance of information resources in avoiding publication bias 
363 SRMAs out of the 375/817 SRMAs that statistically examined publication bias 
searched Medline. To understand the additional benefit of resources when searched 
alongside Medline, I identified the resources that were negatively associated with 
publication bias using a logistic regression model (n=363). Table 2 lists the resources 
negatively associated with publication bias (adjusted odds ratio <1) in all SRMAs 
significant at P=0.20, stratified by endpoint type. Appendix 6 provides a list of all 
resources and their associated adjusted odds ratios. 
Of the information resources, Scopus was significantly associated with low publication 
bias, while CTG exhibited a strong trend towards low publication bias. On repeating the 
procedure for SRMAs looking at only safety outcomes, low publication bias was 
associated with CTG.  
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Discussion 
Searching from a large and diverse body of studies is key to valid evidence generation in 
systematic reviews and meta-analyses (SRMA). However, little evidence-based guidance 
exists on which resources to search, resulting in haphazard searches of cherry-picked 
resources. I conducted a systematic review of the information resources searched by 
SRMAs published from 2005 to 2016. The best predictor of use of alternate resources is 
the type of journal publishing the SRMA. Although search guidelines have not directly 
contributed to the increase in registries or grey resources, the diversity of searches after 
!!
Table 2. Information sources that, when searched alongside Medline, are negatively associated with publication bias. 
 
 
Resource( Adjusted(odds(ratio((95%(confidence(limits)( P(value(
For(all(endpoints((n=363)(
Scopus! 0.32((0.12D(0.88)( 0.03(
ClinicalTrials.gov! 0.33((0.09D1.20)( 0.09(
Conference(proceedings! 0.56((0.27D1.15)( 0.12(
Other(specialized(literature(database! 0.37((0.10D1.40)( 0.14(
For(safety(endpoints((n=120)(
ClinicalTrials.gov! 0.02((0.00D0.56)( 0.02(
Scopus! 0.17((0.02D1.72)( 0.13(
For(other(endpoints((n=188)(
Conference(proceedings! 0.14((0.01D1.28)( 0.08(
Scopus! 0.25((0.05D1.25)( 0.09(
SportDiscus! 0.10((0.01D1.52)( 0.10(
 
 
Using a bivariate logistic regression model, adjusted for SRMA characteristics and use of other resources, we derived odds ratios (OR) 
for association of information resources and the finding of publication bias in the SRMAs that already searched Medline. We list the 
information resources negatively associated with publication bias, significant at P=0.2, for SRMAs examining any endpoint (n=363), 
SRMAs examining safety endpoints (n=120), and SRMAs examining other endpoints (n=188). No resource was significantly 
negatively associated with publication bias at P=0.2 for only efficacy endpoints (n=148). Odds ratios for all resources are shown in 
Appendix 6. !
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propounding of 2012 guidelines has increased. However, overall, there is still 
considerable sequestration in use of published literature databases. Among the resources, 
searching CTG and Scopus were significantly associated with low publication bias. 
Although many studies have shown that registries are underutilized in SRMAs, factors 
associated with greater use have not been studied. I found that, adjusted for other 
covariates, methods journals are most likely to use trial registries. The methods journals 
were also associated with increased use of other resources including conference 
proceedings, dissertations and all grey literature resources combined. This implied that 
the policies implemented by editors of such journals significantly affect SRMA search 
strategies. At the same time, SRMAs in both general and specialized medical/surgical 
journals rarely searched trial registries and other grey literature resources. This is 
concerning because such journals not only form the majority of journals publishing 
SRMAs and the likeliest to be read by clinicians who might practice healthcare based on 
the results of SRMAs. Encouragingly, I did find an increasing trend in the use 
specifically of CTG over time.  
Although several guidelines exist directing the use of information resources in 
conducting SRMAs, advice regarding use of resources storing unpublished data is mostly 
ambiguous.[18] In their review examining the clarity of SRMA guidelines, Boden et al. 
find that only three provide procedural guidance on using databases such as registries to 
identify unpublished trials: the Cochrane MECIR guideline (2012),[34] the Centre for 
Reviews Dissemination (CRD) guideline (2009)[47], and the Preferred Reporting Items 
for Systematic Reviews and Meta-analyses (PRISMA-P) guideline (2015).[48] Of the 
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three, although CRD was the earliest to suggest use of registries to find unpublished 
studies, the Cochrane MECIR guideline published in December, 2012 were the first to 
“mandate” searching CTG, ICTRP and other grey literature resources. Hence, to examine 
whether the guidelines had influenced the practice of CTG search in SRMAs I tried 
identifying differences in trends of database usage before and after 2014 (having a one 
year lag after promulgation of Cochrane MECIR guideline in December 2012). I found 
that in spite of a general increase from 2005 to 2016, there was no significant effect of the 
guidelines on the absolute rate of CTG search 2014 onwards. This suggests that mere 
guideline recommendations are insufficient to ensure a wider use of registries as 
information resources in SRMAs. While a survey by Tetzlaff et al., 2006 finds a majority 
of meta-analysts and editors agree that unpublished data should be searched, such 
practice is not implemented routinely.[49] All journal editors, mirroring the practices in 
methods journals, should insist upon searching registries. However, search guidelines did 
seem to increase the use of diverse resources as evidenced by a progressively higher 
network density after 2014. This can explain Kicinski and colleagues’ finding of a 
decrease in publication bias evidenced in relatively recent SRMAs.[50]  
The purpose of searching multiple resources for SRMAs is to avoid missing relevant 
research that may not have been indexed in one particular database. Little is gained by 
searching multiple databases if there is significant overlap in content covered by them. 
Efficient search strategies should aim to retrieve the maximum number of studies using 
only the most essential information resources: not only because several data resources 
require paid subscriptions, but also searching each resource requires substantial time, 
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skilled manpower, and eventual elimination of duplicate studies. Therefore, searching 
data resources diverse in their study coverage should be the aim of the review strategy. 
However, I found evidence of sequestration of similar resources in the SRMA searches. 
For example, the most common two resources to co-occur in searches were Medline and 
EMBASE. Medline, EMBASE, and the Cochrane libraries form the most used triad. 
Similar sequestration was noted among all databases focusing on published literature. 
Conversely, co-searching diverse resources such as databases mining published literature 
and registries or databases mining published literature and grey literature sources were 
relatively rare. Such practice is questionable because there is considerable overlap 
between published literature resources like Medline and EMBASE, and studies suggest 
searching EMBASE in addition to Medline provides little incremental benefit.[19] On the 
other hand, Cochrane CENTRAL databases mainly mine data from Medline and 
EMBASE (only 0.02% of studies deposited in CENTRAL were not from either Medline 
or EMBASE).[51] Such sequestration of search resources seems reflective of blindly 
following prevalent practice, rather than well thought-out strategies. In such scenarios, 
instead of investing time searching studies from similar types of resources, researchers 
should diversify the nature of their information resources based on the type of studies 
covered (published/unpublished). 
Finally, of the resources used in SRMAs, searching Scopus and CTG were associated 
with statistical findings of no publication bias. The benefit of Scopus may be explained 
by the fact that it has 100% coverage of multiple resources including Medline, EMBASE, 
Compendex, World textile index, Fluidex, Giobase, and Biobase. Additionally, it has 
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approximately 20% more citation coverage than Web of Science, and covers patents and 
web literature as sources of grey literature.[52] CTG usage showed a trend towards low 
publication bias in general, while this link was stronger in studies with safety endpoints. 
The benefit of CTG can be explained by its coverage of unpublished trial reports as 
evidenced in previous research.[26] The fact that CTG provides a wider coverage of 
safety data than published articles may explain its benefit in SRMAs with safety studies. 
[27,29] 
This study has several limitations. First, I look at use of information resources in search 
strategy and link this to publication bias. This is, however, an indirect linkage, as mere 
searching of a certain resource may not lead to finding additional studies in individual 
cases. Moreover, I use statistically measured publication bias results as end points in the 
above analysis. However, many studies do not report statistical tests to identify 
publication bias, simply because determination of publication bias by most statistical tests 
is imperfect. However, due to our relatively large sample size, I aimed to find an 
association between finding publication bias and information resources. Also, an ideal 
scenario for an interrupted time series analysis is to have more endpoints both before and 
after the intervention than I did. However, since the Cochrane guideline was a recent 
implementation, meaningful distal time points were unavailable. 
In conclusion, this study provides evidence that registries and other forms of grey 
literature in SRMA are mostly used in methods journals only, and recommendations in 
best practice guidelines may not be sufficient for widespread use of such resources. I 
additionally found that even SRMAs that search multiple sources tend to search similar 
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resources, rather than databases with diverse coverage. This study provides supports 
using Scopus and CTG in addition to Medline search to reduce publication bias.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
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CHAPTER 3 
Concordance of data on serious adverse events and death between 
ClinicalTrials.gov, journal articles and FDA medical reviews 
Introduction 
The issue of discrepancy of data between CTG and articles reach beyond concerns about 
lack of research reproducibility: it also prevents building confidence regarding the 
usability of such data in secondary research. Journal articles have limited publishing 
space, and do not report all safety data.[53,54] Since secondary researchers 
systematically review published articles, the unpublished safety data often remain 
ignored in meta-analysis research, resulting in a falsely skewed impression favoring drug 
efficacy that may ignore existing (yet under-published) safety issues. Increased use of 
wider safety data reported in registries may pose a solution, provided such data is correct. 
Importantly, previous works reporting discrepancy between CTG and published articles 
implicitly assume the veracity of article data, just because they are peer reviewed.[29] 
However, the peer reviewers do not get access to the patient level data, and do not 
perform re-analysis of the data.[55] Thus, the peer review process cannot guarantee 
correctness of article data. On the other hand, the FDA reviews patient level data, and 
makes these reviews publicly available.[30] Moreover, while the consequences of data 
manipulation in articles can mostly be academic or ethical, manipulated data presented to 
the FDA will have legal implications.[31,32] Thus, FDA reviews are more appropriate 
gold standards to judge to data accuracy in registries.  
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In this chapter, I compared the concordance of safety data among the three resources: 
FDA medical reviews (the reference standard), CTG and journal articles, (the test 
resources), in a random sample of new molecular entities (NMEs) approved by the FDA 
between 2013-2015.  
Methods 
Searching and eligibility 
Of the new molecular entities (NMEs) approved from 2013 to 2015, I randomly sampled 
30% of the medications, stratified by their year of approval. Thereafter, I extracted safety 
information from trials considered “pivotal” for the FDA approval of the respective 
drugs. I excluded a drug from the final analysis if 1. Relevant trial reports were available 
within all three resources, 2. Cohort sizes of the trials described in all three resources 
were comparable, and 3. Data from two or more pivotal trials were pooled to evaluate 
safety in the FDA reports (since pooled data would increase uncertainty about the 
inconsistency within the sources).  
Data sources and extraction 
I manually extracted data from the three resources:  the FDA, the CTG, and the published 
articles. Data from the FDA was extracted from the website Drugs@FDA, from the 
medical reviews enlisted within the drug approval notices. The pivotal trials used to 
assess safety by the FDA reviewer were identified and relevant data were extracted. All 
safety information was taken from the most recent NME submission cycle, or if enough 
detail wasn’t provided in that, the last cycle report where safety details were provided.  
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Thereafter, CTG was searched for the corresponding trial reports using the drug names 
and trial acronyms. Published articles were identified from the Medline indexed articles 
that are automatically linked to the relevant CTG report. That the reports extracted from 
the three resources described the same trial was confirmed by comparing the cohort sizes 
in the three reports. 
Outcomes of interest 
For all drugs, I noted the numbers of deaths (from all causes), and number of serious 
adverse events (SAE) noted in each pivotal trial reports from the three resources. These 
were the primary outcomes of interest since these safety endpoints have uniform 
definitions across the resources. From each resource, I noted the outcome denominators, 
i.e., the total number of individuals exposed to each treatment group (receiving 
NME/control), and the numerators, i.e., the number (or proportion) of patients with at 
least one outcome. If the numerators were reported as percentages in any report, those 
percentages were converted to full numbers and rounded up. I calculated outcome rates 
by determining the percentage of patients exposed to treatment who had outcomes.  
Additionally, I noted the total period of observation for which each endpoint within each 
report was recorded. I calculated the observation period as the time difference between 
the trial initiations till the cut-off date for database closure for the analysis, as noted in 
each of the three resources. 
To look at reporting concordance among the resources for more granulated safety 
endpoints, I selected a subgroup of cancer NMEs. This is because the secondary safety 
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endpoints are better described across resources for cancer medications. For this 
evaluation, I selected all medications included in our final analysis that were L 
(anticancer and immunomodulatory) drugs according to the Anatomic Therapeutic 
Chemical drug classification.[56] I selected the safety endpoints mentioned in the 
“Adverse reactions” section described the product label associated with the NME. My 
rationale was that: 1. Since the risk-benefit assessments of the NMEs of these 
medications of concern, the safety endpoints of these drugs are likelier to be subject of 
quantitative meta-analysis in future assimilations, and should thus be reported 
consistently across the trial reports, and 2. These safety endpoints are described using 
“Preferred terms” from the MedDRA vocabulary across the resources, thus making the 
case definitions uniform across the data sources. I compared the reported numbers for 
these safety events of all severities; for CTG, I added the numbers reported as “Serious 
AEs” and “Other AEs” to arrive at the total numbers for “all grade AEs”. 
Analysis 
I assessed discordance between the point estimates of the extracted numerators, 
denominators, and calculated AE rates as reported within the three resources. I estimated 
any mismatch between the index and reference resources on numerators, denominators, 
outcome rates, and observation time as a percentage change from the value in the 
reference standard:  
(ValueFDA- Valuetest_resource)  X 100 
ValueFDA 
 
I considered mismatches over ±30%1 of the FDA value as being significant.  
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I then measured if there was any consistent pattern in over/under reporting of endpoints 
in either CTG or articles as compared to the FDA reviews. To explain differences in 
reporting, I compared the cut-off time frames used for reporting of the safety endpoints. 
Numerical data were summarized as medians and interquartile ranges while categorical 
data were presented as frequencies. To compare between groups of numerical data I used 
Mann-Whitney test, whereas to compare between categorical data, chi-squared analysis 
was used. I calculated linear correlations between numerical data using Spearman’s Rho. 
I considered a P value lower than 0.05 to be statistically significant. All statistical 
analyses were performed using Stata version 14.[45] 
Results 
Out of a total of 113 NMEs approved between 2013-2015, I selected a 30% random 
sample of 38 NMEs stratified over approval year. Of these, 13 NMEs met our eligibility 
criteria. The sampling process and reasons for exclusion are described in Figure 1, the 
most common cause of exclusion being the pooling of safety data across trials in the FDA 
medical reviews. Four medications were approved in 2013 (Riociguat, Conjugated 
estrogens/Bazedoxifene, Afatinib, Trametinib), four in 2014 (Ceftolozane/Tazobactam, 
Ramucirumab, Peginterferon beta-1a, Siltuximab), and five in 2015 (Edoxaban, 
Ivabradine, Sacubitril/Valsartan, Ixazomib, Aripiprazole lauroxil). Six out of the 13 
medications were ATC class L (anticancer and immunomodulatory drugs), three were 
class C (cardiovascular drug), and one each of classes B (drug for blood and blood 
forming organs), G (sex hormone), J (anti-infective), and N (drug for nervous system). 
Eleven of the 13 drugs contributed one trial each, while two had two trials each. Of the   
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Figure 1. Selection trials of new molecular entities (NMEs) approved by the United 
States Food and Drug Administration (FDA). [Abbreviations: ATC= Anatomic 
Therapeutic Chemical; CTG= ClinicalTrials.gov; Drug classes: A: Alimentary 
tract and metabolism; B: Blood and blood forming organs; C: Cardiovascular system; D: 
Dermatologicals; G: Genito-urinary system and sex hormones; H: 
Systemic hormonal preparations, excluding sex hormones and insulins; J: 
Antiinfectives for systemic use; L: Antineoplastic and immunomodulating agents; M: 
Musculo-skeletal system; N: Nervous system; R: Respiratory system; V: Various]  
113#NME#approved#by#the#FDA#from#201392015##
(27#in#2013,#41#in#2014,#45#in#2015)#
ATC#classiﬁcaHon:#A#(15.9%),#B#(3.5%),#C#(7.1%),#D#(3.5%),#
#G#(2.7%),#H#(0.9%),#J#(12.4%),#L#(33.6%),#M#(0.9%),#N#(7.1%),##
R#(4.4%),#V#(8.0%)#
#
30%#random#sample#straHﬁed#by#year:#resulHng#in#
38#NMEs#(9#in#2013,#14#in#2014,#15#in#2015)#
ATC#classiﬁcaHon:#A#(15.8%),#B#(2.6%),#C#(10.5%),#D#(2.6%),#
#G#(5.3%),#J#(10.5%),#L#(28.9%),#M#(2.6%),#N#(2.6%),##
R#(5.3%),#V#(13.2%),#(No#diﬀerence#from#populaHon#P=0.9)#
!
#
13#NMEs#[4#in#2013(Riociguat,#Conjugated#
estrogens/Bazedoxifene,#AfaHnib,#TrameHnib),#4#in#
2014#(Ce`olozane/Tazobactam,#Ramucirumab,#
Peginterferon#beta91a,#Siltuximab),#and#5#in#
2015(Edoxaban,#Ivabradine,#Sacubitril/Valsartan,#
Ixazomib,#Aripiprazole#lauroxil)]#
ATC#classiﬁcaHon:#B#(7.7%),#C#(23.1%),#G#(7.7%),#J#(7.7%),#L#
(46.1%),#N#(7.7%)##
#
#
#
#
Excluded#NMEs#
17:#had#data#from#pivotal#trial#pooled#with#other#studies#
7:#did#not#have#data#in#either#arHcles#or#CTG#
1:#cohort#sizes#did#not#match#between#the#three#resources#
#
#
#
#
15#trials#selected#(11#of#the#13#drugs#contributed#
one#trial#each,#while#2#had#2#trials#each.#)#
#
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15 trials, four trials had three arms each [two test arms (with a different dose of test drug 
each) and a control arm], while the rest 11 two arms each (one test and one control arm). 
For the ease of analysis, in trials that had three arms, I converted the two active drug arms 
into one by adding across the numerators and denominators. A total of 60 point-estimates 
(30 numerators and 30 denominators) were to be compared across three resources per 
endpoint. 
There were frequent mismatches between the index and reference sources in data (either 
numerators or denominators) in NME arms for both death (72% for ClinicalTrials.gov, 
53% for articles) and SAEs (30% for ClinicalTrials.gov, 30% for articles). A similar 
pattern of frequent but minor deviations in mismatch for death and SAE was also seen for 
control arms as shown in Table 1. However, mismatches of >30% from FDA values were 
infrequent for outcome rates in in both resources [for death rates, 18% cases in 
ClinicalTrials.gov and 6% cases in articles; for SAE rates, never in either resource]. 
When CTG and articles were compared with FDA reviews, I did not find any systematic 
tendency towards over- or underreporting in the endpoints death or SAE [median change 
in risk ratio of death rate from FDA vs CTG as opposed to that in FDA vs article= 0% vs 
0%, P= 0.87; median change in risk ratio of SAE rate from FDA vs CTG as opposed to 
that in FDA vs article= 0% vs 0%, P= 0. 0.51].  
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Table 2 shows the mismatches in data on safety endpoints mentioned in product labels of 
the six anticancer/immunomodulatory drugs in our sample. Mirroring the pattern in death 
and SAE, frequent but minor deviations were seen for “Adverse reactions” for the 
selected anticancer drugs. Frequencies of any mismatches for adverse reactions were 
similar in ClinicalTrials.gov and articles for NME arms (80% in ClinicalTrials.gov, 62% 
in articles, P=.11) as well as controls (64% in ClinicalTrials.gov, 44% in articles, P=.13).  
I explored whether discrepancies between the data sources can be explained by 
differences in time frames of cohort observation. In general, such data was poorly 
reported in the articles (unclear in 4/15 articles). The time frames were available from all 
three resources in 10/15 trials. In those ten trials, the percentage change in observation 
period from FDA reviews and CTG or articles were comparable (median percentage 
change from FDA in CTG 2.2% vs that in articles 1 %, P= 0.47). While the time frames 
were rarely exactly same between FDA and either of the test sources, there were no 
significant correlations between the changes in time frame with respect to FDA review 
and changes in event rates (correlation coefficient between percentage difference in time 
frame vs percentage difference in event rates active arms: FDA vs CTG for death Rho= -
0.20, P= 0.58; FDA vs articles for death Rho= 0.006, P= 0.98; FDA vs CTG for SAE, 
Rho= 0.08, P=  0.77; FDA vs article for SAE Rho= -0.20, P=  0.65). This makes 
differences in time frames of cohort observation unlikely to be the chief source of the 
discordances in event rates. 
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Table 2. Mismatches in reporting of safety outcomes mentioned in “Adverse Reaction” section of product labels for anticancer drugs 
between FDA reviews, ClinicalTrials.gov, and published articles. 
 
aNME= new molecular entity 
New molecular entity 
(Approval year) 
Adverse reaction  
(in MedDRA preferred term) 
Percentage mismatch in outcome rate at 
ClinicalTrials.gov compared to FDA 
Percentage mismatch in outcome rate in articles 
compared to FDA 
NMEa arm Control arm NME arm Control arm 
Trametinib 
(2013) 
 
Rash 0.0 0.0 0.0 0.0 
Diarrhea 0.0 0.0 0.0 0.0 
Lymphedema -9.1 0.0 Not reported Not reported 
Afatinib 
(2013) 
 
 
 
 
 
Diarrhea -129.2 -8.7 -127.1 26.1 
Rash/Dermatitis acneiform -60.0 0.0 -126.7 36.4 
Stomatitis -22.5 26.7 -132.4 -13.3 
Paronychia -124.1 0.0 -124.1 0.0 
Dry skin -122.6 0.0 -116.1 0.0 
Decreased appetite -127.6 0.0 -62.1 0.0 
Pruritus -119.0 0.0 -104.8 0.0 
Siltuximab 
(2014) 
 
 
 
Pruritus 4.3 0.0 4.3 0.0 
Increased weight 0.0 0.0 0.0 0.0 
Rash -17.4 -33.3 21.7 0.0 
Hyperuricemia 0.0 100.0 0.0 100.0 
Upper respiratory tract infection 26.9 20.0 26.9 20.0 
Ramuciruab (2014) 
 
Hypertension 10.3 -22.2 2.6 0.0 
Diarrhea 0.0 10.0 Not reported Not reported 
PEGylated-Interferon 
Beta-1a (2014) 
 
 
 
 
 
Injection site erythema 0.1 -0.2 0.0 0.0 
Influenza-like illness 0.3 -0.2 0.0 0.0 
Pyrexia 0.3 1.1 0.0 0.0 
Myalgia -0.9 60.4 0.0 60.5 
Chills 0.1 -0.2 0.0 0.0 
Injection site pain -0.6 -0.2 0.0 0.0 
Injection site pruritus -1.5 -0.2 0.0 0.0 
Ixazomib (2015) 
 
 
 
 
 
 
Diarrhea 95.4 97.7 -8.3 -7.2 
Constipation 99.2 98.9 -3.0 -4.7 
Thrombocytopenia 94.5 86.1 -53.0 -58.8 
Peripheral neuropathy 0.0 0.0 -161.4 -169.7 
Nausea 97.8 100.0 -12.7 -7.1 
Peripheral edema 98.9 98.5 -10.7 -10.9 
Vomiting 97.5 100.0 -6.0 -8.0 
Median (interquartile ranges) of percentage mismatches 0.0 (-17.4 to 10.2) 0.0 (-0.2 to 60.4) 0.0 (-62.1 to 0.0) 0.0 (-4.7 to 0.0) 
	  40	  
Discussion 
Built with an original aim to enhance research transparency, trial registries that mandate 
reporting of trial results also lend themselves as sources of publicly available trial 
data.[57] However, accuracy of such data has been called into suspicion upon findings 
that they do not always match corresponding reports in published articles, thus 
questioning the usability of registry data for secondary research.[28,29] I compared 
safety data in CTG and articles with FDA reviews to find that the discrepancies in both 
test resources, while equally prevalent, usually are of modest magnitude.  
This work has implications for the use of use of publicly available safety data in registries 
for secondary research. First, since the differences are small, and not due to biased over 
or under-reporting, safety data from registries can be considered as an alternative to 
published article data. There are several reasons to encourage such practice: since 
accessing articles often require paid subscriptions to journals, performing secondary 
research becomes a monopoly of resource-rich settings, a present-day reality that ignores 
scientific perspective of the underprivileged.[58] Since data in registries are publicly 
available, such inequitable situations would be challenged. Moreover, since a significant 
proportion of large trials remain unpublished in journals while being reported in 
registries, increased use of registries in secondary research may help avoid publication 
bias, particularly in safety data.[26,27] 
This work has several limitations. First, to use FDA reviews as gold standards, I limit our 
sample to only NMEs. Since any report on NMEs are under considerable scrutiny from 
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regulators, researchers, clinicians and the public, the slightness of differences between 
FDA reports and CTG/articles in case of NMEs may not extrapolate to trials performed in 
later stages of a drugs life cycle. Second, the observation periods I attempted to extract 
from all three resources are only rough estimates, and may not be accurate. Given that the 
event rates change with time frames, all resources should precisely identify the 
observation periods for reporting safety data to ensure greater transparency. Third, the 
sample is small. However, the randomized sampling procedure may ensure external 
validity of this research. 
In conclusion, thisresearch shows that differences in data between FDA reviews, CTG, 
and articles are prevalent but small. If FDA reviews are considered gold standards, 
neither CTG nor articles systematically over- or underreport rates of safety events. Future 
work needs to identify whether the small differences in safety data between the resources 
qualitatively or quantitatively affect results of meta-analyses. 
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CHAPTER 4 
Examining reproducibility of published meta-analyses using data at 
ClinicalTrials.gov downloaded by an automatic extraction tool 
Introduction 
The finding of frequent, minor, yet equally prevalent differences in data between CTG 
and FDA reviews as opposed to journal articles and FDA reviews raises the question that 
whether it would make a difference if data at CTG is used instead of article data to 
conduct of met-analysis research. If such interchangeability is established, it can 
potentially make meta-analysis research faster and more accurate, since the uniformly 
reported data at CTG can be automatically downloaded in analysis-ready formats, 
eliminating the necessity of the error-prone and time consuming process of manual data 
extraction from articles. 
In this chapter, I describe whether the data at CTG can reproduce the results in the 
published meta-analysis articles. As a part of this work, I led the development of web-
based interactive tool (EXACT, Extracting Accurate efficacy and safety information 
from ClinicalTrials.gov: http://bio-nlp.org/EXACT/) that allows automated extraction of 
trial data by end-users.  
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Methods 
Selection of published meta-analysis articles for reproduction 
Because mandatory reporting of trial results at CTG is relatively recent,[59] I searched 
for meta-analyses of drugs recently approved by FDA.[60] I listed the new molecular 
entities (NMEs) approved by FDA in the year 2013, and randomly selected three (10% 
sample) of those NMEs. I then searched PubMed for meta-analyses involving those 
drugs. As a proof of concept, I selected one meta-analysis article per drug. I excluded 
meta-analyses that 1. Used Bayesian or other model-based methods, 2. Did not include 
both efficacy and safety endpoints, 3. Did not have trial reports available in both 
published articles and CTG results, or 4. Had ambiguous endpoints. When more than one 
paper for a drug satisfied all these criteria, I selected the one that had the largest number 
of endpoints.  
Ensuring validity of our meta-analysis methods  
To ensure I was using the same methods as the published meta-analyses, I repeated the 
meta-analyses of endpoints in the published articles using data manually extracted from 
the primary study articles. I considered a published meta-analysis to have been 
reproduced by us using data from primary study articles if 1. The relative risk (RR) was 
within +/-20% of the RR in the published SR, and 2. The P-value remained on the same 
side of 0.05 as in the published SR. This validated I were using the same methods as the 
published meta-analyses. Having established that I was using identical methods as the 
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published meta-analyses for the reproduced endpoints, I repeated the meta-analyses for 
those endpoints using data extracted from CTG. 
Extracting data from CTG automatically using EXACT, a web-based tool 
To automatically extract data from CTG, I led the development of a web-based tool 
called EXACT, (Extracting Accurate efficacy and safety information from 
ClinicalTrials.gov: http://bio-nlp.org/EXACT/) with Matthew Cornell, our software 
developer (Please see preface for credits).  The EXACT implementation is a Python 
program[61] comprising a library to parse records expressed in the CTG XML format, a 
Flask web application[62] that allows the user to customize which data are desired, and 
library routines to extract those data in a structured format. The XML parsing library 
contains 30 functions in categories corresponding to general information in the CTG 
website (trial title, study type, conditions, interventions, and design) and routines to 
extract data from the sections on baseline, outcome, participant flow, and reported events. 
The library consists of about 1800 lines of code, about one-third for internal tests to 
ensure proper functioning.  
On the server side, the application requires two databases: A MySQL[63] database that 
contains the extracted numerical data, and an Apache Solr[64] instance that indexes the 
fields to be searched for by one of the application’s two search features (indication and/or 
intervention search, and trial body search). The trial body search covers the fields 
‘arm_group’, ‘brief_summary’, ‘brief_title’, ‘condition’, ‘intervention’, and 
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‘official_title’. Information on the intervention or the indication is automatically 
downloaded for the user. Figure 1 describes the steps involved in developing the tool.  
 
Figure 1. Diagram showing development of EXACT 
 
 
 
	  46	  
Sources of data for EXACT 
CTG allows users to download data either via the “Clinical Trials Transformation 
Initiative Aggregate Analysis of ClincalTrials.gov” (CTTI AACT) database[65] or as 
XML files from a search result.[66] we found it difficult to process the CTTI database 
(which is updated infrequently), so we chose to program from the search list. We used 
our Python library[61] to process the XML files and populate a MySQL database with the 
extracted trial information and data.  
Internal validation of the tool 
The program was developed using Extreme Programming’s Test Driven Development 
methodology,[67] which resulted in extensive coverage of all library functions via 25 
tests to ensure proper functioning (about 600 lines of code). Test inputs were an arbitrary 
selection of eight actual CTG XML files chosen to represent a range of trials, along with 
hand-collected expected outputs for them, obtained from each trial’s CTG results page.  
With the resulting application, a user of EXACT can initiate a search with the unique 
CTG identifier for a particular trial. Thereafter, assuming the trial results have been 
reported at CTG, the user can download all trial data, or can select any of 1. reporting 
groups, 2. period (main trial period/follow-up period) and participant flow, 3.  outcome 
measures, 4. serious adverse events, and 5. other adverse events. Figure 2 shows the user 
interface and Appendix 7 is a manual to use EXACT. 
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Figure 2. EXACT’s user interface: A. Screenshot of trial result reported at 
ClinicalTrials.gov; B. Screenshot of six steps through which the user specifies the items 
to be downloaded (Appendix describes a user manual); C. Screenshot of data extracted in 
excel format. 
 
Use of the CTG data for meta-analysis 
To validate the use of CTG data thus extracted, I re-conducted meta-analyses published 
in three peer-reviewed articles with data extracted from CTG. I considered a meta-
analysis to have been reproduced if 1. The relative risk (RR) was within +/-20% of the 
RR in the published SR, and 2. The p-value remained on the same side of 0.05 as in the 
published SR. All analyses used Stata version 14 and used the same random-effects or 
fixed-effect model as in the published SR. 
Results 
From the 27 NMEs approved by the FDA in 2013, I randomly selected three: Simeprevir, 
Trametinib, and Vortioxetine. Figure 3 describes the article selection, Table 1 describes 
the articles selected, and Appendix 8 describes the reasons for excluding other SR 
articles.  
The three SR articles contained meta-analyses of a total of 28 endpoints. From manually 
extracted data I were able to reproduce results for 25 endpoints (details of the other three 
endpoints are in Appendix 9). Then I sought to reproduce the meta-analysis results for 
these 25 endpoints using the CTG data extracted by EXACT. The 25 outcomes required 
extraction of 498 pairs of data elements from original articles and from CTG via EXACT. 
[Besides 480 data points for 23 endpoints (4 from Qu et al., 2015, 7 from   
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Figure 3. Flowchart for selection of meta-analyses reproduced using data manually 
extracted from Original articles and data extracted by EXACT from 
ClinicalTrials.gov  
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Abdel-Rahman et al., 2016, and 12 from Li et al., 2016), 18 data elements (hazard ratio 
and its two 95% confidence limits from each of six trials (four for progression-free 
survival and two for overall survival) used in Abdel-Rahman et al., 2016)]. 87% of the 
extracted numbers matched between the two sources (details in Appendix 10). An equal 
amount of trial data was available from original articles and CTG for 20 of the 25 
outcomes. More trial data were available from original articles for one efficacy outcome 
(hazard ratio for overall survival in Trametinib), and CTG provided more data for four 
safety outcomes (hypertension and acneiform dermatitis for Trametinib; hyperhidrosis 
and somnolence for Vortioxetine).  
Table 1. Selected systematic reviews. 
Systematic review Comparison Number of 
RCTs pooled 
Endpoints selected for meta-analysis 
Qu et al., 2015 Comparison of Simpeprevir + 
Peginterferon + Ribavirin versus 
Peginterferon + Ribavirin in HCV 
infection 
6 Sustained virological response at 12 
weeks, Rapid virological response, Serious 
adverse events, Discontinuation 
Abdel-Rahman et 
al., 2016 
Comparison of BRAF inhibitors 
+Trametinib versus BRAF 
inhibitors in BRAF-mutated 
melanoma 
4 Hazard ratio for progression-free survival, 
Hazard ratio for overall survival, Overall 
response rate, Diarrhea, Hypertension, 
Decreased ejection fraction, Acneiform 
dermatitis, Pyrexia, Squamous cell 
carcinoma 
Li et al., 2016 Vortioxetine versus Duloxetine in 
major depressive disorder  
5 Response rate, Remission rate*, 
Nausea, Constipation, Hyperhydrosis, 
Diarrhea , Dizziness , Dry mouth, 
Fatigue, Insomnia, Somnolence, 
Nasopharyngitis*, Decreased appetite*, 
Headache, Vomiting 
RCT= randomized controlled trial, HCV= Hepatitis C virus, BRAF= a gene encoding B-
Raf protein. 
* Endpoint that could not be reproduced !!!!!!!!!!!!!
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Using the data extracted from CTG, I was able to reproduce results for 22 endpoints 
(88%). The median difference in the risk ratio between published meta-analysis and 
reproduction using CTG data was 0.005 (Interquartile range: minus 0.0015 to 0.0175) for 
the efficacy endpoints, and 0.01 (Interquartile range: 0 to 0.02) for the safety endpoints. 
The results are shown in Table 2. [I was unable to reproduce meta-analyses for weighted 
mean differences in Li et al. 2016 because the primary articles for this SR did not 
consistently report measures of dispersion, Appendix 11. Replication using data at CTG, 
where standard deviations were reported, is presented in Appendix 12.] 
Approximately 10 hours were spent collecting data from published articles, and 
approximately 4 hours were spent using EXACT. Thus, EXACT reduced the time of data 
extraction by 60%.  
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Table 2. Results of meta-analyses from published systematic review and meta-analyses (SRMA) 
using data manually extracted from original articles and from ClinicalTrials.gov using EXACT.!
Outcomes marked with * could not be reproduced. 
NA= Not available 
 
 
 
Outcomes 
 
 
 
Type of outcome 
Relative risk (95% confidence limits) P values I2 statistic 
Published 
SRMA 
Data from 
original 
article 
Data from 
CTG via 
EXACT 
Published 
SRMA 
Data from 
original 
article 
Data from 
CTG via 
EXACT 
Published 
SRMA 
Data from 
original 
article 
Data from 
CTG via 
EXACT 
Qu et al.2015, Simeprevir 
Sustained 
Virological 
Response at 12 
weeks 
Efficacy 1.69 
(1.37-2.08) 
1.692 
(1.37-2.08) 
1.692 
(1.37-2.08) 
<0.001 <0.001 <0.001 0.824 0.824 0.824 
Rapid Virological 
Response 
Efficacy 9.57 
(5.82-15.73) 
9.57 
(5.82-15.73) 
9.68 
(5.88-15.95) 
< 0.001 <0.001 <0.001 0.636 0.636 0.639 
Serious Adverse 
Events 
Safety 0.67 
(0.47-0.94) 
0.67 
(0.47-0.94) 
0.65 
(0.46-0.92) 
0.023 0.024 0.017 0 0 0 
Discontinuation 
 
Safety 
 
1.26 
(0.58-2.74) 
1.033 
(0.65- 1.73) 
0.98 
(0.44-2.19) 
0.566 0.899 0.970 0 0 0 
Abdel-Rahman et al., 2016, Trametinib 
Hazard ratio for 
Progression-Free 
Survival 
Efficacy 0.56 
(0.49-0.64) 
0.54 
(0.47-0.62) 
0.54 
(0.47-0.62) 
< 0.00001 <0.001 <0.001 NA 0.548 0.548 
Hazard ratio for 
Overall Survival  
Efficacy 0.7 
(0.58-0.84) 
0.57 
(0.46-0.68) 
0.67 
(0.52-0.83) 
0.00001 <0.001 <0.001 NA 0.486 0 
Overall Response 
Rate 
Efficacy 1.35 
(1.16-1.58) 
1.34 
(1.23-1.45) 
1.34 
(1.23-1.45) 
0.0002 <0.001 <0.001 NA 0.13 0.13 
Diarrhea Safety 1.3 
(1.3-1.49) 
1.3 
(1.13-1.48) 
1.29 
(1.13-1.47) 
0.0002 <0.001 <0.001 NA 0.909 0.895 
Hypertension* Safety 1.22 
(0.99-1.52) 
1.22 
(0.98-1.51) 
1.32 
(1.08-1.62) 
0.07 0.068 0.005 NA 0.247 0.458 
Decreased 
ejection fraction* 
Safety 4.63 
(2.56-8.37) 
4.63 
(2.56-8.36) 
3.35 
(2.02-5.55) 
<0.00001 <0.001 <0.001 NA 0.629 0.642 
Acneiform 
dermatitis 
Safety 1.61 
(1.03-2.53) 
1.61 
(1.02-2.53) 
1.58  
(1.12-2.21) 
0.04 0.038 0.008 NA 0.436 0.15 
Pyrexia Safety 1.98 
(1.72-2.27) 
1.97 
(1.71-2.27) 
2.18 
(1.91-2.49) 
<0.00001 <0.001 <0.001 NA 0.822 0.87 
Squamous cell 
carcinoma* 
Safety 0.16 
(0.1-0.25) 
0.16 
(0.1-0.25) 
0.2 
(0.11-0.36) 
<0.00001 <0.001 <0.001 NA 0.382 0.224 
Li et al., 2016, Vortioxetine 
Response rate Efficacy 0.83 
(0.77-0.89) 
0.83 
(0.78-0.89) 
0.83 
(0.77-0.89) 
<0.001 <0.001 <0.001 0 0 0 
Nausea Safety 0.7 
(0.56-0.87) 
0.75 
(0.61-0.94) 
0.7 
(0.61-0.81) 
0.001 0.01 <0.001 NA 0.854 0.754 
Constipation Safety 0.47 
(0.34-0.64) 
0.45 
(0.32-0.65) 
0.45 
(0.32-0.65) 
<0.001 <0.001 <0.001 NA 0 0 
Hyperhydrosis Safety 0.35 
(0.23-0.55) 
0.31 
(0.19-0.5) 
0.29 
(0.18-0.45) 
<0.001 <0.001 <0.001 NA 0 0 
Diarrhea Safety 0.74 
(0.57-0.97) 
0.72 
(0.53-0.97) 
0.72 
(0.53-0.97) 
0.03 0.03 0.03 NA 0 0 
Dizziness Safety 0.51 
(0.37-0.69) 
0.51 
(0.33-0.8) 
0.51 
(0.33-0.8) 
<0.001 0.004 0.004 NA 0.624 0.624 
Dry mouth Safety 0.5 
(0.39-0.63) 
0.48 
(0.35-0.65) 
0.52 
(0.31-0.85) 
<0.001 <0.001 0.01 NA 0.295 0.79 
Fatigue Safety 0.45 
(0.32-0.64) 
0.44 
(0.29-0.67) 
0.44 
(0.29-0.67) 
<0.001 <0.001 <0.001 NA 0.163 0.163 
Insomnia Safety 0.65 
(0.46-0.92) 
0.64 
(0.42-0.96) 
0.64 
(0.42-0.96) 
0.016 0.033 0.033 NA 0 0 
Somnolence Safety 0.33 
(0.21-0.52) 
0.31 
(0.19-0.5) 
0.33 
(0.21-0.5) 
<0.001 <0.001 <0.001 NA 0 0 
Headache Safety 0.93 
(0.77-1.13) 
0.93  
(0.74-1.16) 
0.93 
(0.74-1.16) 
0.468 0.523 0.523 NA 0 0 
       Vomiting  
Safety 
0.7 
(0.45-1.09) 
0.72 
(0.45-1.16) 
0.72 
(0.45-1.16) 
0.110 0.176 0.176 NA 0 0 
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Discussion 
This research suggests that, although mismatches occur between data published in 
original articles and data at CTG, they seldom qualitatively alter the results of meta-
analyses. This aligns with studies showing that most mismatches in data at CTG are 
minor.[68] The strength of our results lies in the random selection of the SR articles and 
the wide range of endpoints, encompassing both efficacy and safety outcomes. 
Additionally, we developed a web-based tool to automatically extract data from CTG.  
Although previous reports have emphasized the necessity of searching CTG alongside 
original articles as a source of additional data,[12,69] our study suggests that data from 
CTG, when used as the primary source, reproduce similar meta-analysis results. Thus, 
this work recommends use of CTG data particularly for safety results, which are often 
reported in greater detail at CTG.[27]  
Our web-based tool also provides a way to accelerate the process of data extraction for 
meta-analyses research. Currently users have no publicly available method to extract the 
vast amounts of trial data available at CTG without advanced programming. Cepeda et 
al., constructed such an implementation, but it is proprietary.[70] EXACT fills this gap 
and reduces the time required for primary data extraction. Our tool can enhance the use of 
CTG by making data extraction from it substantially less laborious. Because EXACT 
makes no extraction errors, compared with many in manual extraction of data from 
published articles, it should also reduce errors in primary data extraction.[37] As a 
verification tool, EXACT could also be useful to journal reviewers and regulatory 
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authorities who might want to check the CTG site for the validity of data entered,[71] and 
tally CTG reports with the articles published and regulatory submissions corresponding 
to these studies. This capability will add to research transparency and reproducibility, 
areas of specific concern at present.[72] 
Data from CTG reproduced the results most meta-analyses of data from original articles. 
EXACT fills a current gap in medical informatics tools, helping meta-analysis research 
by providing an application that automatically extracts results data from CTG. 
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CHAPTER 5 
Conclusions 
In conclusion, the work described in this dissertation looks into the current scenario of 
use of information resources in SRMAs to find that registries, although is an 
underutilized resource, is associated with the finding of low publication bias in SRMAs 
with safety endpoints. I verify the accuracy of the safety data at CTG by examining its 
differences with FDA drug reviews. Finally, I repeat meta-analysis using CTG data to 
show that most meta-analysis results are reproduces using CTG data. This work supports 
the use of CTG data in meta-analyses of safety endpoints. 
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